Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy’s Doxycycline Capsules, 40 mg*, are supplied in bottle counts of 30.

Please click here to see the full prescribing information - https://www.drreddys.com/pil/doxycycline-capsules.pdf.

*Each capsule contains: 26 mg immediate-release pellets and 14 mg delayed-release pellets equivalent to 40 mg of anhydrous doxycycline, USP.

ORACEA® is a trademark of Galderma Holdings, S.A.